EUR 1.82
(2.0%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -0.73 EUR | 41.13% |
2022 | -1.24 EUR | -65.33% |
2021 | -0.75 EUR | -5.63% |
2020 | -0.71 EUR | -3636.84% |
2019 | -0.02 EUR | -146.91% |
2018 | 0.04 EUR | 127.0% |
2017 | -0.15 EUR | 77.27% |
2016 | -0.66 EUR | -135.71% |
2015 | -0.28 EUR | 40.43% |
2014 | -0.47 EUR | 22.95% |
2013 | -0.61 EUR | 12.86% |
2012 | -0.70 EUR | -233.33% |
2011 | -0.21 EUR | 54.35% |
2010 | -0.46 EUR | -9.52% |
2009 | -0.42 EUR | -200.0% |
2008 | -0.14 EUR | 46.15% |
2007 | -0.26 EUR | -992.44% |
2006 | -0.02 EUR | 80.17% |
2005 | -0.12 EUR | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q1 | 0.42 EUR | 282.61% |
2024 Q2 | -0.18 EUR | -145.24% |
2023 Q3 | -0.25 EUR | -108.33% |
2023 Q1 | -0.13 EUR | 59.38% |
2023 Q4 | -0.23 EUR | 8.0% |
2023 Q2 | -0.12 EUR | 7.69% |
2023 FY | - EUR | 41.13% |
2022 Q2 | -1.58 EUR | -558.33% |
2022 FY | - EUR | -65.33% |
2022 Q4 | -0.32 EUR | -141.03% |
2022 Q3 | 0.78 EUR | 149.37% |
2022 Q1 | -0.24 EUR | -114.04% |
2021 Q2 | -0.64 EUR | -113.33% |
2021 Q1 | -0.30 EUR | -1210.04% |
2021 FY | - EUR | -5.63% |
2021 Q3 | -1.60 EUR | -150.0% |
2021 Q4 | 1.71 EUR | 206.88% |
2020 Q3 | -0.42 EUR | -55.56% |
2020 FY | - EUR | -3636.84% |
2020 Q2 | -0.27 EUR | -1914.93% |
2020 Q1 | -0.01 EUR | -278.67% |
2020 Q4 | -0.02 EUR | 94.55% |
2019 Q2 | -0.08 EUR | -257.8% |
2019 FY | - EUR | -146.91% |
2019 Q4 | 0.01 EUR | 1975.0% |
2019 Q3 | -0.00 EUR | 99.49% |
2019 Q1 | 0.05 EUR | -29.38% |
2018 Q2 | -0.02 EUR | -200.0% |
2018 Q1 | 0.02 EUR | 150.0% |
2018 FY | - EUR | 127.0% |
2018 Q4 | 0.07 EUR | 277.0% |
2018 Q3 | -0.04 EUR | -100.0% |
2017 Q2 | -0.03 EUR | -50.0% |
2017 Q4 | -0.04 EUR | 0.0% |
2017 Q3 | -0.04 EUR | -33.33% |
2017 FY | - EUR | 77.27% |
2017 Q1 | -0.02 EUR | 32.2% |
2016 Q4 | -0.03 EUR | 67.22% |
2016 FY | - EUR | -135.71% |
2016 Q3 | -0.09 EUR | 80.43% |
2016 Q2 | -0.46 EUR | -557.14% |
2016 Q1 | -0.07 EUR | -723.53% |
2015 Q2 | -0.12 EUR | -56.05% |
2015 Q1 | -0.08 EUR | 40.85% |
2015 FY | - EUR | 40.43% |
2015 Q4 | -0.01 EUR | 89.28% |
2015 Q3 | -0.08 EUR | 33.92% |
2014 Q3 | -0.05 EUR | 44.44% |
2014 FY | - EUR | 22.95% |
2014 Q1 | -0.13 EUR | 13.33% |
2014 Q2 | -0.09 EUR | 30.77% |
2014 Q4 | -0.13 EUR | -160.0% |
2013 Q3 | -0.19 EUR | 5.0% |
2013 Q4 | -0.15 EUR | 21.05% |
2013 FY | - EUR | 12.86% |
2013 Q1 | -0.12 EUR | 47.83% |
2013 Q2 | -0.20 EUR | -66.67% |
2012 Q3 | -0.11 EUR | 0.0% |
2012 Q4 | -0.23 EUR | -109.09% |
2012 FY | - EUR | -233.33% |
2011 FY | - EUR | 54.35% |
2010 FY | - EUR | -9.52% |
2009 FY | - EUR | -200.0% |
2008 FY | - EUR | 46.15% |
2007 FY | - EUR | -992.44% |
2006 FY | - EUR | 80.17% |
2005 FY | - EUR | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
Boiron SA | 2.06 EUR | 135.437% |
Laboratorios Farmaceuticos Rovi, S.A. | 3.20 EUR | 122.813% |
Vetoquinol SA | 4.70 EUR | 115.532% |
AB Science S.A. | -0.20 EUR | -265.0% |
Nanobiotix S.A. | -1.08 EUR | 32.407% |
PHAXIAM Therapeutics S.A. | -5.00 EUR | 85.4% |
Vivoryon Therapeutics N.V. | -1.12 EUR | 34.821% |
BioSenic S.A. | -0.21 EUR | -247.619% |
ABIVAX Société Anonyme | -3.43 EUR | 78.717% |
Formycon AG | 4.76 EUR | 115.336% |